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25 Abstract
26 Familial isolated pituitary adenomas (FIPA) is one of the most frequent conditions associated with an 
27 inherited presentation of pituitary tumors.  FIPA can present with pituitary adenomas of any secretory/non-
28 secretory type. Mutations in the gene for the aryl-hydrocarbon receptor interacting protein (AIP) have been 
29 identified in approximately 20 % of FIPA families and are the most frequent cause (29%) of pituitary 
30 gigantism. Pituitary tumors in FIPA are larger, occur at a younger age and display more aggressive 
31 characteristics and evolution than sporadic adenomas.  This aggressiveness is especially marked in FIPA 
32 kindreds with AIP mutations. Special attention should be paid to young patients with pituitary gigantism 
33 and/or macroadenomas as AIP mutations are prevalent in these groups. Duplications on chromosome 
34 Xq26.3 involving the gene GPR101 lead to X-linked acrogigantism (X-LAG), a syndrome of pituitary 
35 gigantism beginning in early childhood; three kindreds with X-LAG have presented in the setting of FIPA.  
36 Management of pituitary adenomas in the setting of FIPA, AIP mutations and GPR101 duplications is often 
37 more complex than in sporadic disease due to early onset disease, aggressive tumor growth and resistance 
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42 Introduction
43 Pituitary adenomas are intracranial tumors that occur in 10-15 % of individuals in autopsy series and in 20-
44 38% of those undergoing CT/MRI (Ezzat, et al. 2004; Molitch 2009) (Freda, et al. 2011). The vast majority 
45 of these adenomas, however, are incidentally-discovered, very small, non-functioning pituitary 
46 microadenomas with no clinical impact. The medical significance of pituitary adenomas lies in the group 
47 of tumors that are sufficiently large and/or hormonally active to cause signs and symptoms.  The prevalence 
48 of these clinically-relevant pituitary adenomas is of the order of 1 case per 1000 of the general population 
49 (Daly, et al. 2006b). The management of clinically relevant pituitary adenomas is often challenging and 
50 involves a multidisciplinary team of endocrinologists, neurosurgeons, ophthalmologists and radiologists. 
51 Despite their benign nature, some pituitary adenomas may have aggressive behavior and pose additional 
52 morbidity for patients. 
53 To date, the molecular mechanisms behind the development of the majority of pituitary adenomas 
54 are not well understood. Usually, these tumors are sporadic, but approximately 5 % have a known genetic 
55 or familial background (Daly, et al. 2009). Pituitary pathology has been described in several syndromes of 
56 multiple endocrine neoplasia (MEN). Among them, MEN1 is the most common and accounts for about 3% 
57 of all pituitary adenomas (Scheithauer, et al. 1987). MEN1 is caused by germline inactivating mutations in 
58 MEN1 gene on chromosome 11q13 (Chandrasekharappa, et al. 1997). Carney complex (CNC) is another 
59 inherited syndrome that can include familial pituitary adenomas (usually acromegaly) and is predominantly 
60 caused by inactivating mutations in the gene encoding the type 1A regulatory subunit of protein kinase A 
61 (PRKAR1A) (Carney, et al. 1985; Casey, et al. 1998). Inherited pituitary adenoma risk is also associated 
62 with the recently characterized syndromes of multiple endocrine neoplasia type 4 (MEN4) caused by 
63 inactivating mutations of CDKN1B gene (Pellegata, et al. 2006), or in the setting of the pheochromocytoma-
64 paraganglioma with pituitary adenoma association (3PA) that is due to mutations in succinate 
65 dehydrogenase (SDH) or MAX genes (Daly, et al. 2018; Xekouki, et al. 2015).
66
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67 The emergence of FIPA 
68 Individual cases of familial acromegaly and gigantism arising in a non-syndromic setting have been 
69 reported in literature ever since the first description of the disease by Pierre Marie (Beckers, et al. 2018; de 
70 Herder 2009). Although these first records concerned only acromegaly, by the 1990s several kindreds with 
71 familial corticotropinomas, prolactinomas and non-functioning pituitary adenomas (NFPA) were also 
72 reported (Berezin and Karasik 1995; Salti and Mufarrij 1981; Yuasa, et al. 1990). The concept of familial 
73 isolated pituitary adenomas (FIPA) emerged in the late 1990s with the publication of an initial cohort of 27 
74 families with pituitary adenomas, including acromegaly as well as other secretory phenotypes, in the 
75 absence of signs and symptoms of MEN1 and CNC (Beckers 2004; Valdes Socin, et al. 2000; Verloes, et 
76 al. 1999). Currently, FIPA is defined as the presence of pituitary adenomas of any type in at least two related 
77 members of the same family in the absence of clinical and genetic evidence of other known syndromic 
78 diseases ((Daly, et al. 2006a); Table 1)). It is considered to account for approximately 2 % of all clinically 
79 relevant pituitary adenomas and up to 3.8 % when considering only hormonally active tumors (Daly et al. 
80 2006a; Marques, et al. 2017). Genealogical data indicate that FIPA is inherited in autosomal dominant 
81 manner with variable penetrance that can reach 33 % in some kindreds (Daly et al. 2006a; Daly, et al. 2007; 
82 Naves, et al. 2007). Depending on the functional type of the adenoma, FIPA can be divided into 
83 homogeneous – when pituitary tumors of the same type are present in all affected family members, and 
84 heterogeneous – with different pituitary adenomas within the kindred. Compared to sporadic pituitary 
85 adenomas, FIPA patients are diagnosed significantly earlier (on average 4 years). In multigenerational 
86 families descendants are diagnosed at considerably younger age than their parents or grandparents, 
87 especially in homogeneous FIPA (Daly et al. 2006a). In the overall cohort of FIPA, prolactinomas are the 
88 most frequent secretory subtype (37.5%) (Beckers, et al. 2013). When prolactinomas occur in 
89 heterogeneous FIPA, they present with more aggressive characteristics, like higher rates of suprasellar 
90 expansion and invasion of the cavernous sinus. Somatotropinomas are the second most common pituitary 
91 tumors in FIPA accounting for 35 % of FIPA and somatoprolactinomas are observed in another 6.4 % of 
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92 cases.  They are almost equally divided between homogeneous and heterogeneous families but, unlike FIPA 
93 prolactinomas, GH-secreting adenomas are more aggressive when occurring in a homogeneous setting.  In 
94 homogeneous FIPA, acromegaly can be diagnosed up to 10 years earlier with tumors more frequently 
95 displaying extrasellar growth as compared to heterogeneous kindreds and sporadic populations (Beckers et 
96 al. 2013). Non-secreting adenomas occur predominantly in heterogeneous families and account for 14.5 % 
97 of FIPA patients. They are diagnosed earlier and are more frequently invasive than their sporadic 
98 counterparts. Corticotropinomas, gonadotropinomas and thyrotropinomas are rare in FIPA (2.9%; 2.0%, 
99 0.5 % respectively). They are usually associated with other adenoma types in heterogeneous kindreds 
100 (Beckers et al. 2013).
101 Molecular genetics of FIPA
102 Original linkage studies in familial somatotropinomas detected loss of heterozygosity on 
103 chromosome 11q13 in a region different to the MEN 1 locus (Gadelha, et al. 1999; Yamada, et al. 1997). 
104 Genetic analyses in this genomic region in large Finnish kindreds with heterogeneous FIPA identified 
105 inactivating mutation in the gene for aryl hydrocarbon receptor interacting protein (AIP) on chromosome 
106 11q (Vierimaa, et al. 2006). Its causative role in FIPA was later confirmed in other affected families and by 
107 now over 100 different mutations of AIP have been described (Beckers et al. 2013; Daly, et al. 2010; 
108 Hernandez-Ramirez, et al. 2015; Pepe, et al. 2019). 
109 AIP is a tumor suppressor gene but the exact molecular mechanisms leading to pituitary 
110 tumorigenesis have not been completely elucidated. It is widely expressed in various tissues and in normal 
111 pituitary it is associated with secretory granules in somatotrope and lactotrope cells (Leontiou, et al. 2008). 
112 Homozygous AIP-/- knockout mice develop lethal cardiovascular defects early in the embryonic period 
113 suggesting that AIP plays a role in cardiovascular development (Lin, et al. 2007). Heterozygous AIP+/- 
114 animals, however, develop a phenotype that is very similar to human pituitary disease with the majority of 
115 the mice presenting with aggressive somatotropinomas (Raitila, et al. 2010), although some variability 
116 exists in relation to older age at onset in mice versus humans (Lecoq, et al. 2016).
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117 The AIP gene consists of six exons and encodes a 37kDa cytoplasmic protein of 330 amino-acid 
118 residues with highly conserved sequence among different species (Trivellin and Korbonits 2011). Its N-
119 terminal end displays significant homology with immunophilins but appears not to possess such functional 
120 activity. The carboxy terminal half of the protein contains three tetratricopeptide repeats (TPR) and a 
121 terminal α7-helix which mediate numerous protein-protein interactions (Morgan, et al. 2012). AIP was 
122 initially described as negative regulator of X antigen of hepatitis B virus (Kuzhandaivelu, et al. 1996). 
123 Furthermore, it was shown to interact also with Epstein-Barr virus-encoded nuclear antigen 3 (EBNA-3) 
124 suggesting that AIP may play a role in virus induced pathology (Kashuba, et al. 2006). One of the most 
125 thoroughly characterized interactive partners of AIP is the aryl hydrocarbon receptor (AhR). It belongs to 
126 the family of ligand activated transcription factors and modulates cellular responses to various xenobiotic 
127 toxins, such as dioxins, as well as some endogenous compounds such as cAMP (Trivellin and Korbonits 
128 2011). In the absence of ligands AhR binds to two molecules of the 90kDa heat shock protein (HSP90) and 
129 the co-chaperones AIP and p23 to form a multiprotein complex in the cytoplasm. The activation of the 
130 complex by its xenobiotic ligand leads to dissociation of the HSP90 dimer and conformational change of 
131 AhR that exposes its nuclear localization sequence. In the subsequent nuclear translocation, the complex 
132 AhR-AIP binds to the aryl hydrocarbon receptor nuclear translocator (ARNT), also known as HIF1β, and 
133 promotes the transcription of specific genes coding various drug metabolizing enzymes (Ramadoss and 
134 Perdew 2005). Ligand activated AhR may also modulate the activity of other transcription factors such as 
135 estrogen and androgen receptors (Beckers et al. 2013; Trivellin and Korbonits 2011). AIP has been shown 
136 to maintain the stability of the complex by protecting AhR from ubiquitin-dependant degradation (Morales 
137 and Perdew 2007). AhR itself is constitutively active and it was recently shown that AhR may act as tumor 
138 suppressor in the pituitary even in the absence of exogenous ligands (Formosa, et al. 2017). Reduced AIP 
139 expression in pituitary adenomas that are positive for AIP mutations is associated with decreased AhR 
140 activity, suggesting an inhibitory function of AhR in pituitary tumorigenesis (Jaffrain-Rea, et al. 2009). 
141 Furthermore, AIP overexpression in cell cultures -including pituitary cell lines- slows down cell 
142 proliferation rates (Leontiou et al. 2008). Apart from stabilizing the AhR complex, AIP may also be 
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143 involved in several other nuclear receptor pathways by being able to bind to the peroxisome proliferator-
144 activated receptor α, the glucocorticoid receptor, and β-thyroid hormone receptor 1 (Beckers et al. 2013). 
145 AIP can also interact with the transcript of the RET protooncogene - a tyrosine kinase receptor that is 
146 involved in cell growth and regulation of apoptosis. The domain responsible for the pro-apoptotic activity 
147 is the same as that responsible for the AIP interaction (Vargiolu, et al. 2009).  This RET-AIP binding 
148 presumably prevents the formation of a complex between AIP and survivin - an inhibitor of apoptosis and 
149 cell cycle regulator. In the absence of AIP, survivin is subject to proteosomal degradation with consequent 
150 increase in apoptosis (Kang and Altieri 2006).  However, this interplay of AIP, RET and survivin probably 
151 does not have a role in pituitary tumorigenesis. AIP has been shown to participate in the transfer of 
152 mitochondrial preproteins from the cytosol by interacting with the translocator of outer mitochondrial 
153 membrane 20 (TOMM20) (Yano, et al. 2003). The list of interacting partners of AIP has recently been 
154 updated with some cytoskeletal proteins, especially TUBB and TUBB2A, and it may be suggested that loss 
155 of AIP impairs the organisation of the cytoskeleton and contributes to the more invasive nature of AIP-
156 mutant pituitary adenomas (Hernandez-Ramirez, et al. 2018a).
157 One of the most attractive links between AIP mutations and pituitary tumorigenesis is the 
158 interaction with the cAMP-dependent signaling pathway.  Responsiveness to hypothalamic, peripheral and 
159 paracrine ligands is mediated through either stimulatory or inhibitory G-protein coupled receptors which 
160 use cAMP as second intracellular messenger. In the pituitary, the activation of the cAMP pathway 
161 stimulates cell proliferation and hormonal secretion (Hernandez-Ramirez, et al. 2018b). In pituitary cell 
162 lines in which AIP is knocked down, there is an increase in stimulated cAMP levels (Formosa, et al. 2013). 
163 Loss of AIP has been shown to affect inhibitory G-protein function as AIP-mutant pituitary tumors are 
164 associated with reduced expression of Gαi-2 (Tuominen, et al. 2015). In the anterior pituitary, Gαi proteins 
165 mediate somatostatin-related inhibition of GH and prolactin secretion through somatostatin receptors. Thus, 
166 a defect Gαi-2 function could explain the resistance to somatostatin analogues that is usually observed in 
167 AIP-mutant somatotropinomas (Daly et al. 2010). It has recently been demonstrated that AIP physically 
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168 interacts with both the catalytic (PRKACA) and the regulatory (PRKAR1A) subunits of PKA and likely 
169 regulates its downstream effects (Schernthaner-Reiter, et al. 2018). Another  cAMP pathway interaction of 
170 AIP occurs at the level of phosphodiesterases – the enzymes that inactivate cAMP. It has recently been 
171 shown that AIP-mutant somatotropinomas exhibit reduced expression of PDE4A4 and PDE4A8 possibly 
172 resulting in enhanced cAMP signaling (Bizzi, et al. 2018). 
173 Despite the large and increasing number of molecular interactions of AIP with different regulatory 
174 and functional cascades, none has been proven critical for pituitary tumor development to date. Although 
175 AIP is ubiquitously expressed in the body, no other tumor types except pituitary adenomas have been 
176 consistently associated with AIP mutations suggesting the presence of heavily pituitary-specific 
177 tumorigenic pathways. Also, somatic AIP mutations are not a major cause of pituitary tumorigenesis  
178 (Beckers et al. 2013). Almost 70 % of mutations affect the C-terminal end of the protein.  Nonsense and 
179 frameshift mutations lead to premature stop codons with a resulting truncated protein. A genotype-
180 phenotype correlation has been recently suggested as patients with truncating mutations may develop 
181 pituitary disease at younger age than patients with non-truncating mutations (Hernandez-Ramirez et al. 
182 2015). Pathogenic missense mutations alter protein stability and lead to rapid proteosomal degradation with 
183 a significantly reduced half-life of the mutated protein. Moreover, a direct correlation between half-life of 
184 mutant AIP and age at diagnosis has been documented in patients (Hernandez-Ramirez, et al. 2016). N-
185 terminal mutations have also been proven pathogenic probably by reducing the ability to inhibit cAMP 
186 signalling (Formosa and Vassallo 2017). Apart from point mutations and small insertions and deletions, in 
187 minority of cases larger genomic alterations like exon or whole gene deletions may be present. Such 
188 genomic rearrangements cannot be detected by direct sequencing and require the use of multiple ligation-
189 dependant probe amplification (MLPA) (Beckers et al. 2013; Georgitsi, et al. 2008).
190
191 Clinical implications of AIP mutations
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192 AIP mutations explain the pathology of about 20% of FIPA families (Beckers et al. 2013) and they 
193 are associated with some specific clinical characteristics that differentiate them from patients with wild type 
194 AIP (Table 1). Somatotropinomas are the most frequent secretory phenotype representing more than 70% 
195 of all tumors in AIP-mutated FIPA kindreds and half of them exhibit co-secretion of prolactin. In total, 
196 acromegaly and prolactinoma families make up almost 90 % of all cases, the rest are mainly NFPA.  Single 
197 cases of thyrotropinomas and Cushing’s disease have also been described in association with AIP mutations 
198 (Beckers et al. 2013). AIP-mutation related somatotropinomas develop at significantly younger age and 
199 experience a more aggressive evolution that their non-mutated counterparts. Mutated tumors are also 
200 significantly larger and they are often already macroadenomas with invasive characteristics and frequent 
201 extrasellar expansion at presentation (Daly et al. 2010). Due to the young onset of disease, 29-30% of AIP 
202 positive GH-secreting adenomas manifest clinically with gigantism (Daly et al. 2010; Rostomyan, et al. 
203 2015).  Control of GH excess and tumor growth is also difficult to achieve and maintain in AIP mutation 
204 carriers because of poorer responsiveness to first generation somatostatin analogues in these patients. In the 
205 long term, AIP mutant tumors often require multiple surgeries and radiotherapy (Daly et al. 2010).  A recent 
206 report, however, indicates that pasireotide, a second-generation somatostatin analogue, may be effective in 
207 providing hormonal control and tumor shrinkage in AIP-positive acromegaly patients (Daly, et al. 2019b).  
208 AIP–mutated prolactinomas also present with large tumors size and invasive features. Resistance to 
209 dopamine agonists may be observed in 50 % of them, resulting in the need for surgery and/or radiotherapy 
210 (Daly et al. 2010).  Due to rapid growth, AIP mutation related pituitary adenomas can undergo apoplexy 
211 (Figure 1), so there should be particular vigilance for AIP mutations among young pituitary apoplexy 
212 patients or in those with a familial history of pituitary apoplexy (Villa, et al. 2011; Xekouki, et al. 2013).
213 Screening for AIP mutations
214 The identification of AIP mutations may be beneficial for patients and their relatives by potentially 
215 providing early diagnosis and higher likelihood of successful treatment, although no formal outcome studies 
216 of screening have been performed. Currently, genetic screening in unselected pituitary adenoma patients is 
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217 not justified because the prevalence of AIP mutations in such population is very low – 0-4 % (Barlier, et al. 
218 2007; Cazabat, et al. 2012). However, focused screening may be recommended in some specific high-risk 
219 groups (Figure 2). The highest probability of AIP mutation is in patients with pituitary gigantism where 
220 such genetic alterations are found in 29 % (Rostomyan et al. 2015). AIP mutations are present in almost 12 
221 % of patients younger than 30 years with early onset large macroadenomas (Tichomirowa, et al. 2011) and 
222 more than 20% in pediatric patients with macroadenomas (Stratakis, et al. 2010) making these populations 
223 good candidates for genetic screening. FIPA patients represent another readily identifiable group in which 
224 testing for AIP mutations is warranted, as they are present in about 20% of kindreds. Development of risk 
225 stratification models to inform genetic testing guidelines remains a work in progress, and the most 
226 informative criteria continue to be those identified above (i.e. gigantism, young onset, FIPA kindreds, large 
227 macroadenomas).  A recent study suggests that somatostatin analog resistance is not a helpful additional 
228 criterion to identify potential AIP mutation-related acromegaly cases (Daly, et al. 2019a).  
229 There are no guidelines for the management of AIP mutation positive and familial pituitary 
230 adenomas and their treatment largely follows the current guidelines for their sporadic counterparts in terms 
231 of indications and therapeutic approaches. Detailed physical examination for extra-pituitary involvement 
232 and comprehensive family history should be initially performed and any suspicion for syndromic conditions 
233 such as MEN1 and Carney complex should be confirmed when considering patients and their families for 
234 genetic testing.  Unaffected AIP mutation carriers should be offered complete clinical, biochemical and 
235 MRI evaluation at baseline and regular endocrinological surveillance after that.  More challenging is the 
236 situation in FIPA families without identifiable AIP mutations. In such cases it may be appropriate to inform 
237 unaffected subjects about signs and symptoms of pituitary disease and encourage them to seek 
238 endocrinological consultation if such symptomatology occurs.  The common presence of pituitary 
239 gigantism in patients with AIP mutations means that particular attention needs to be paid to pediatric 
240 mutation carriers.  Early diagnosis and a decreased delay before effective treatment have been shown to 
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241 improve final height in patients with pituitary gigantism (Rostomyan et al. 2015) and efficient management 
242 of AIP mutation carriers with incipient somatotropinomas could help to limit long term overgrowth.
243
244 GPR101 and FIPA
245 We recently described a novel syndrome of early childhood onset pituitary gigantism due to chromosome 
246 Xq26.3 duplications called X-linked acrogigantism (X-LAG) (Beckers, et al. 2015; Trivellin, et al. 2014).  
247 Patients with X-LAG are typically born at normal size following unremarkable pregnancies, but over the 
248 first 12-36 months of life develop rapid increases in length and weight due to GH/IGF-1 hypersecretion 
249 from pituitary somatotrope-somatomammotrope macroadenomas and/or hyperplasia (Beckers et al. 2015; 
250 Trivellin et al. 2014).  Growth hormone releasing hormone (GHRH) excess in some cases studied indicates 
251 that X-LAG may be a multi-level disease involving both the hypothalamus and anterior pituitary (Daly, et 
252 al. 2016a).  Treatment of the pituitary tumor in X-LAG is complex due to the young age of affected children 
253 and relatively large tumor size.  In addition, first-line medical therapy with somatostatin analogs like 
254 octreotide and lanreotide is usually ineffective to control GH/IGF-1 excess and height gain.  The GH 
255 receptor antagonist, pegvisomant, has proven effective in IGF-1 and growth control in X-LAG cases.  The 
256 chromosome Xq26.3 duplication includes the gene GPR101, that encodes an orphan G-protein coupled 
257 receptor whose expression is highly elevated in tumors of X-LAG patients (Trivellin et al. 2014).  This 
258 duplication usually occurs spontaneously either as a constitutive duplication or in a somatic mosaic state, 
259 the latter occurring in sporadic males with X-LAG (Daly, et al. 2016b).  The chromosome Xq26.3 
260 duplication involving GPR101 can also be inherited in an X-linked dominant manner, and all carriers of 
261 the duplication are affected by pituitary gigantism.  To date, three FIPA kindreds have been described in 
262 which the underlying cause of isolated somatotropinomas was proven to be X-LAG.  These all involved 
263 transmission of the Xq26.3 duplication from affected mother to affected son (two sons in one kindred and 
264 one son each in the other two kindreds).  In two of the families, pregnancy occurred following assisted 
265 reproduction techniques that were necessary due to extensive pituitary tumor surgery and secondary 
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266 gonadotropin deficiency.  In one familial case the Xq26.3 duplication was diagnosed prenatally on 
267 chorionic villus sampling and led to a perinatal diagnosis of a pituitary adenoma secreting high levels of 
268 GH and prolactin within the first month of life (Gordon, et al. 2016; Wise-Oringer, et al. 2019). Further 
269 details about GPR101 and X-LAG are discussed by Trivellin et al in the current issue of Endocrine related 
270 Cancer (Trivellin et al. 2020). 
271
272 Conclusions
273 The definition of FIPA almost 20 years ago and the discovery of AIP as its causative gene represent 
274 important advances in our expanding knowledge about the genetic background of pituitary adenoma 
275 development.  The more recent description of X-LAG due to GPR101 duplications provides a novel 
276 mechanism by which families with pituitary gigantism can rarely present in the FIPA setting.  However, 
277 much remains to be explored in FIPA as in almost 80 % of FIPA kindreds the genetic causes remain 
278 unknown. Besides the wide spectrum of functions that have been ascribed to AIP the precise molecular 
279 pathways that lead to pituitary tumorigenesis are yet to be fully explained.  Consensus guidelines for genetic 
280 testing, management and follow-up of FIPA patients are still to emerge, and require long term monitoring 
281 studies to arrive at the most clinically relevant recommendations. 
282
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482 Figure 1.  Contrast enhanced MRI images of showing pituitary macroadenomas in two sisters from an AIP 
483 mutation positive FIPA family. Both patients presented at a young age (12 and 17 years) with symptoms 
484 related to tumor size (headache and visual loss); and on imaging and on surgery there was evidence of 
485 incipient pituitary apoplexy.  Reproduced with permission from Villa et al.(Villa et al. 2011)
486
487 Figure 2.  Potential at-risk groups for pituitary adenomas related to AIP germline mutations.  The highest 
488 prevalence of AIP mutations (green boxes) occurs in pituitary gigantism (29%) and FIPA (20% of 
489 kindreds).  An intermediate risk (yellow boxes) occurs among pediatric pituitary adenoma patients 
490 (particularly GH secreting adenomas) and in patients with aggressive, large or invasive macroadenomas 
491 with disease/symptom onset during adolescence and early adulthood.  AIP mutation patients with 
492 aggressively growing pituitary adenomas can develop apoplexy, so a history of symptoms or radiologic 
493 findings suggestive of apoplexy should be considered.  Groups of pituitary adenoma patients that are 
494 unselected for age at onset, tumor characteristics or family history have a low level of AIP mutations in 
495 international studies (red box). Similarly, the presence of SSA resistance in acromegaly or DA resistance 
496 in prolactinomas alone (without other aggressive/early onset tumor features) does not help in identifying 
497 patients with AIP mutations (red box).  DA: dopamine agonist; SSA: somatostatin analog.
498
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Table 1. Summary of clinical features in patients with FIPA, AIP mutations and GPR101 
duplications.
Familial isolated pituitary adenomas (FIPA)
 Occurs when at least two related members of the same kindred have isolated pituitary 
adenomas (i.e. syndromic conditions affecting other endocrine organs like MEN1 are not 
present)
 Can present homogeneously (all affected members of the same kindred have the same 
pituitary adenoma subtype) or heterogeneously (different pituitary adenoma subtypes across 
the kindred).
 Generally FIPA cases have an earlier onset and have a larger tumor size than sporadic non-
FIPA pituitary adenoma cases
 Genetic causes are present in about 20% of kindreds
o AIP mutations 
o GPR101 duplications (rare presentation)
AIP mutations
 Autosomal dominant disease with incomplete penetrance
 About 20% of AIP mutation carrier will develop a pituitary adenoma
 All secretory and non-secretory pituitary adenoma subtypes can occur
o Predominantly (>90%) somatotropinomas, mixed GH and prolactin secreting tumors 
and prolactinomas 
 Prolactin co-secretion is common in AIP mutated somatotropinomas
o Cushing’s disease very rarely associated with AIP mutations
 Early onset tumors affecting children, adolescents, young adults (median age at diagnosis 21 
years)
 Aggressive growth potential leads to large and expansive macroadenomas
 Pituitary apoplexy is a feature of sporadic and familial AIP mutation related pituitary 
adenomas
 Rare cases of whole or partial AIP gene deletions can be missed on genetic sequencing and 
require multiplex ligand specific probe amplification (MLPA) to identify
 Disease control in AIP mutation related acromegaly requires greater cumulative use of 
treatment than non-mutated acromegaly
o Patients with acromegaly and AIP mutation have a decreased responsiveness to first-
generation somatostatin analogs
 There are significantly decreased GH and IGF-1 responses in AIP mutated 
acromegaly
 Tumor shrinkage is significantly lower in AIP mutated acromegaly
o Decreased somatostatin receptor subtype 2 (SST2) can occur in AIP mutated 
somatotropinomas
 Octreotide/lanreotide resistant AIP mutated acromegaly can be controlled 
hormonally and undergo marked tumor shrinkage with to pasireotide 
treatment
GPR101 duplications
 X-linked dominant inheritance (100% penetrance)
 Familial early childhood onset pituitary acrogigantism due to chromosome Xq26.3 
duplications can present as FIPA in rare cases (n=3 kindreds)
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 Inherited duplications involving GPR101 can be transmitted from affected mother to affected 
son
 Lead to early onset (12-36 months of age) pituitary GH and prolactin positive 
macroadenomas with or without hyperplasia
 GHRH levels can be elevated (suggests a hypothalamic-pituitary pathological axis)
 Hyperprolactinemia usually present (responsive to dopamine agonists)
 Patients often require radical neurosurgery as part of a multimodal management scheme
 Somatostatin analogs are typically ineffective in controlling GH/IGF-1 secretion and 
overgrowth
 GH receptor antagonist (pegvisomant) can lower IGF-1 to normal range and control growth
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